Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) is pleased to announce the appointment of Mr Willem Blijdorp as a Non-Executive Director of the Company.

Mr Blijdorp's appointment comes as Clinuvel prepares the commercial distribution of SCENESSE® for the rare disease erythropoietic protoporphyria (EPP) throughout the European Union.

Mr Blijdorp is the founding member, majority shareholder and a current supervisory Director of B&S International NV, a privately owned Dutch group focused on the wholesale and international trading of luxury and fast moving consumer goods and pharmaceutical products. He managed B&S International for 27 years as CEO and remains actively involved in the company's expansion strategy, helping it to become one of the largest trading houses globally with a compounded annual growth rate of 10% for the past decade. Being recognised for his expertise in merger and acquisitions and leadership, in 2014 Mr Blijdorp was awarded the Ernst & Young Entrepreneur of the Year in the Netherlands.

"I'm delighted to welcome Willem Blijdorp to Clinuvel as a Non-Executive Director," Clinuvel's Chair, Mr Stan McLiesh said. "Clinuvel is transforming from an R&D to a commercial entity, and the Company needed to add relevant expertise to its Board. Willem is a long-standing supporter of Clinuvel and brings a wealth of commercial skills to the Board which will prove invaluable as we advance the commercialisation of SCENESSE® and follow-on products."

- End -

Media contact: Lachlan Hay, Clinuvel Pharmaceuticals Ltd Lachlan.Hay@Clinuvel.comThis email address is being protected from spambots. You need JavaScript enabled to view it.

About Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) is a global biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders. With its unique expertise in understanding the interaction of light and human skin, the company has identified patient populations with a clinical need for photoprotection and another population with a need for repigmentation. These patient groups range in size from 5,000 to 45 million. Clinuvel's lead compound, SCENESSE® (afamelanotide 16mg), a first-in-class drug targeting erythropoietic protoporphyria (EPP), has completed Phase II and III trials in the US and Europe, and has been granted marketing authorisation under exceptional circumstance by the European Medicines Agency for adults with EPP. Based in Melbourne, Australia, Clinuvel has operations in Europe, the US and Singapore.

For more information go to http://www.clinuvel.com.

Clinuvel is an Australian biopharmaceutical company focussed on developing its photoprotective drug, SCENESSE® (afamelanotide 16mg) for a range of UV-related and pigmentary skin disorders. Pharmaceutical research and development involves long lead times and significant risks. Therefore, while all reasonable efforts have been made by Clinuvel to ensure that there is a reasonable basis for all statements made in this document that relate to prospective events or developments (forward-looking statements), investors should note the following:

  • actual results may and often will differ materially from these forward-looking statements;
  • no assurances can be given by Clinuvel that any stated objectives, outcomes or timeframes in respect of its development programme for SCENESSE® can or will be achieved;
  • no assurances can be given by Clinuvel that, even if its development programme for SCENESSE® is successful, it will obtain regulatory approval for its pharmaceutical products or that such products, if approved for use, will be successful in the market place.

Level 14 /190 Queen Street    T +61 3 9660 4900    www.clinuvel.com
Melbourne, Victoria 3000    F +61 3 9660 4999
Australia

distributed by